Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.62
+0.00500.31%
Volume:195.29K
Turnover:317.29K
Market Cap:70.70M
PE:-3.18
High:1.66
Open:1.61
Low:1.61
Close:1.62
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:0.71
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:6.26
PE(LYR):-2.65

Loading ...

Gain Therapeutics to Attend Maxim Growth Summit

Reuters
·
Oct 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 05

Gain Therapeutics Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 05

Analysts Offer Insights on Healthcare Companies: Nexalin Technology, Inc. (NXL) and Gain Therapeutics (GANX)

TIPRANKS
·
Oct 03

Gain Therapeutics highlights promising Parkinson’s Phase 1b data

TIPRANKS
·
Oct 01

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

GlobeNewswire
·
Oct 01

Gain Therapeutics - to Initiate Phase 2 Rexaceract Trial in Q1 2027 - SEC Filing

THOMSON REUTERS
·
Oct 01

Gain Therapeutics Plans Phase 2 Trial of Rexaceract in Parkinson's Disease for Q1 2027 Start

Reuters
·
Oct 01

Gain Therapeutics to Present Long-Term Phase 1b Extension Data for Parkinson’s Drug Rexaceract at MDS Congress

Reuters
·
Sep 30

Gain Therapeutics Names CEO as Interim CFO

TIPRANKS
·
Sep 29

Gain Therapeutics - Gene Mack to Continue as President and CEO While Serving as Interim CFO - SEC Filing

THOMSON REUTERS
·
Sep 29

Gain Therapeutics - Gianluca Fuggetta to Resign as Principal Financial Officer Effective Sept 30, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 29

Gain Therapeutics - Appoints Gene Mack as Interim CFO Effective Oct 1, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 29

Gain Therapeutics CEO Gene Mack Takes Interim CFO Role After Fuggetta Resignation

Reuters
·
Sep 29

Gain Therapeutics CEO Joins ROTH Healthcare Opportunities Conference Panel

Reuters
·
Sep 17

Gain Therapeutics Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Gain Therapeutics Joins H.C. Wainwright Global Investment Conference for Investor Meetings

Reuters
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Prothena (PRTA)

TIPRANKS
·
Aug 15

Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

TIPRANKS
·
Aug 13

Inovio Q2 Net Loss Narrows on Warrant Gain, Lower Costs

Reuters
·
Aug 13